Antiverse was founded by Ben Holland, Murat Tunaboylu and Rowina Westermeir at the Deep Science Ventures Accelerator Programme in 2017. Their objective was to create new enabling technologies in antibody discovery using artificial intelligence that allows for the creation of new therapies against the industry's most challenging targets. Since then, Antiverse has worked with five companies in antibody discovery programmes aimed at several GPCRs, Ion Channels and other challenging targets. In addition, we are developing our own internal pipeline, and have raised around $10.1 million.